How To Navigate a Drug Company’s Good-Faith Inquiry
About this episode
Bibi Wishart discusses how hospitals can effectively navigate good-faith inquiries from drug companies.
Drug companies often initiate good-faith inquiries of covered entities (CEs) to learn more about certain purchase patterns or volumes, but how should hospitals navigate these requests? Bibi Wishart, director of pharmacy at Atrium Health, describes what she’s learned being on the receiving end of these inquiries. Why Do Good-Faith Inquiries Happen? Bibi says the recent rise in good-faith inquiries is tied in part to drug companies gaining access to more varied data sources and expressing a goal of ensuring the information they collect is in line with what they are expecting. She says a variety of different factors could trigger this type of inquiry, including new providers purchasing certain drugs, concerns about duplicate discounts, or confusion around whether a drug is being used in an inpatient or outpatient setting. Hospitals are very complicated, so responding to an inquiry often can be more about educating drug companies about how hospitals dispense drugs. How Should a Hospital Respond? If her hospital receives a communication from a drug company through its authorized official and primary contact, Bibi says she prefers to respond within one or two business days just to…
More episodes of 340B Insight
- How To Calculate How the IRA Will Affect 340B in 2027
- How To Improve 340B Inventory Management
- Lessons From a Pro in Advocating Effectively for 340B
- What Happens After a State Enacts Contract Pharmacy Protections?
- Answering More of Your Top 340B Questions
- Why 340B Rebates Are Off — For Now
Explore listener stats, chart rankings, contacts and more on the 340B Insight podcast page.